

DAFTAR PUSTAKA

1. Kumar V, Abbas AK, Aster JC, Robbins SL. *Robbins Basic Pathology*. Elsevier/Saunders; 2013.
2. Blood W, Cells RB, Essential WHO, et al. In official relations with the World Health Organization. In: ; 2007.
3. Peringatan Hari Thalassemia Sedunia 2016 RSHS | Rumah Sakit Dokter Hasan Sadikin Bandung. <http://web.rshs.or.id/peringatan-hari-thalassemia-sedunia-2016-rshs/>. Accessed January 8, 2019.
4. Cappellini MD. 162 – The Thalassemias. *Goldman-Cecil Med*. 2016;1089-1095.e2. doi:10.1016/B978-1-4557-5017-7.00162-8
5. Hoffbrand, AV. Moss P. *Hoffbrand AV. Hoffbrand's Essential Haematology. 7th Ed. 2016*. 7th ed.; 2016.
6. Taher A, Nathan D, Porter J. Evaluation of Iron Levels to Avoid the Clinical Sequelae of Iron Overload. *Semin Hematol*. 2007;44(SUPPL. 3):2-6. doi:10.1053/j.seminhematol.2007.03.002
7. Temraz S, Santini V, Musallam K, Taher A. Iron overload and chelation therapy in myelodysplastic syndromes. *Crit Rev Oncol Hematol*. 2014;91(1):64-73. doi:10.1016/j.critrevonc.2014.01.006
8. Fadlyana E, Ma F, Elizabeth M, Reniarti L. Correlation between Serum Ferritin Level and Growth Disorders in Children with Thalassemia. 2017;5(3):31-35. doi:10.12691/ajcmr-5-3-2.
9. Vichinsky EP, Bhatia S, Bojanowski J, et al. Standards of Care Guidelines for Thalassemia. *Stand care Guidel Thalass*. 2012:1-27. www.thalassemia.com.
10. Guidelines for the Clinical Care of Patient with Thalassemia in Canada.
11. Health WE, Health O. Adherence to deferasirox among beta-thalassemia

- major children - A cross-sectional study in a tertiary care hospita. *Indian J Child Heal.* 2010;36(1):2016-2019. doi:10.1089/ten.tea.2015.0461
12. Holstein SA HR. Current therapy •. *Hematology.* 2018:444-449. doi:10.1016/B978-0-323-52769-9.00093-3
 13. Robbins, Cotran. *Atlas of Pathology.* 2nd ed.; 2015.
 14. Chapin J, Giardina PJ. *Thalassemia Syndromes.* Seventh Ed. Elsevier Inc.; 2017. doi:10.1016/B978-0-323-35762-3.00040-8
 15. Murray RK, Bender D, Botham KM, Kennelly PJ. *Harpers Illustrated Biochemistry 29th Edition.* 29th ed. McGraw-Hill Education; 2012.
 16. Lanzkowsky P, Lipton JM FJ. *Lanzkowsky P. Pediatric Hematology and Oncology.* Elsevier. 2005;4. 6th ed.; 2016.
 17. Kliegman RM, Stanton BMD, Geme JS, Schor NF. *Nelson Textbook of Pediatrics, 2-Volume Set.* Elsevier Health Sciences; 2015.
 18. Hall JE. *Guyton and Hall Textbook of Medical Physiology E-Book: With STUDENT CONSULT Online Access.* Elsevier Health Sciences; 2010.
 19. Sherwood L. *Introduction to Human Physiology.* Brooks/Cole; 2012.
 20. Lo TO. Adherence to Long - T erm Therapies World Health Organization. 2003:1-11.
 21. Amelia M, Gurnida DA, Reniarti L. Hubungan Kadar Feritin dan Ion Kalsium Serum pada Penyandang Thalassemia Mayor Anak yang Mendapat Transfusi Berulang. *Sari Pediatr.* 2016;16(1):1. doi:10.14238/sp16.1.2014.1-4
 22. R.Safitri, J.Ernawaty DK. Hubungan Kepatuhan Transfusi Dan Konsumsi Obat Kelasi Besi Terhadap Pertumbuhan Anak Dengan Talasemia. *Cybrarians J.* 2015;2(37):1-31. doi:10.12816/0013114
 23. Tejasari RK, Reniarti L, Effendi SH. Faktor Risiko Hiperkoagulasi pada Thalassemia Anak. *Sari Pediatr.* 2016;16(6):427. doi:10.14238/sp16.6.2015.427-33

24. Mardhiyah A, Widianti E, Padjadjaran U. Hubungan Perilaku Sakit Dalam Aspek Psikososial Dengan Kualitas Hidup Remaja Talasemia. 2017;5(1):38-47. <http://ejournal.bsi.ac.id/ejurnal/index.php/jk> 39.
25. Hidup K, Thalassemia P, Aji DN, et al. Faktor–Faktor yang Berhubungan dengan Kualitas Hidup Pasien Thalassemia Mayor di Pusat Thalassemia Departemen Ilmu Kesehatan Anak RSCM. *Sari Pediatr.* 2009;11(2):85-89.
26. Arifna F, Ismy J, Yusuf H. Hubungan Kepatuhan Minum Obat Kelasi Besi Terhadap Perkembangan Seks Sekunder Pada Anak Penderita Talasemia Beta Mayor di Sentral Talasemia RSUDZA Banda Aceh. *J Ilm Mhs Medisia.* 2017;2(3):13-17.
27. Fortin PM, Fisher SA, Madgwick K V., et al. Interventions for improving adherence to iron chelation therapy in people with sickle cell disease or thalassaemia. *Cochrane Database Syst Rev.* 2018;2018(5). doi:10.1002/14651858.CD012349.pub2
28. Satria A, Ridar E, Tampubolon L. Hubungan Derajat Klinis dengan Kadar Feritin Penyandang Talasemia β DI RSUD Arifin Achmad. *Jom Fk.* 2016;3(2):1-9.
29. Mishra AK, Tiwari A. Iron overload in Beta thalassaemia major and intermedia patients. *Maedica (Buchar).* 2013;8(4):328-332. <http://www.ncbi.nlm.nih.gov/pubmed/24790662>. Accessed December 17, 2019.
30. Taher AT, Saliba AN. Iron overload in thalassemia: Different organs at different rates. *Hematology.* 2017;2017(1):265-271. doi:10.1182/asheducation-2017.1.265
31. Lukas S, Nugroho H, Ellora Sudarman V. Correlations Between Oral Iron Chelation Therapy Adherences With Thalassemia Children’S Growth in Anna Medika Hospital. *SciInt(Lahore).* 2018;30(2):247-252. <http://www.sci-int.com/pdf/636579332591484419.edited=Aneela.pdf>.
32. Borgna-Pignatti C, Rugolotto S, De Stefano P, et al. Survival and

complications in patients with thalassemia major treated with transfusion and deferoxamine. *Haematologica*. 2004;89(10):1187-1193.

33. Vekeman F, Sasane M, Cheng WY, et al. Adherence to iron chelation therapy and associated healthcare resource utilization and costs in Medicaid patients with sickle cell disease and thalassemia. *J Med E* 2016;19(3):292-303. doi:10.3111/13696998.2015.1117979

